Sphingosine Kinase 2 Phosphorylation of FTY720 is Unnecessary for Prevention of Light-Induced Retinal Damage

Hui Qi1, Jerome Cole II2, Richard C. Grambergs2, John R. Gillenwater2, Koushik Mondal2, Sufiya Khanam2, Soma Dutta2, Megan Stiles1, Richard L. Proia3, Jeremy Allegood4 & Nawajes Mandal1,2,5

Mammalian Sphingosine kinase 2 is the primary enzyme responsible for phosphorylating FTY720 to its active form, FTY720-P. Systemic FTY720 treatment confers significant protection to murine retinas from light- and disease-mediated photoreceptor cell death. It is not clear whether FTY720-P, FTY720, or both are responsible for this photoreceptor protection. We investigated Sphingosine kinase 2 knockout (Sphk2 KO) mouse retinas, tested their sensitivity to light, and measured what degree of protection from light-induced damage they receive from systemic FTY720 treatment. Sphk2 KO retinas were found to be similar to their wild-type counterparts in sensitivity to light damage. Additionally, FTY720 treatment protected Sphk2 KO retinas from light-induced damage despite significant retardation of FTY720 phosphorylation in Sphk2 KO mice. We conclude that FTY720 serves an active role in preventing photoreceptor cell death. Furthermore, we conclude that the phosphorylation of FTY720 is not necessary to provide this protective effect.

FTY720 is an FDA-approved human drug for relapsing multiple sclerosis (MS) under the trade name Gilenya. In MS, FTY720 has immunosuppressive qualities and acts on immune cells at lymph nodes following conversion to FTY720-phosphate (FTY720-P) in the liver1–4. FTY720 is a synthetic derivative of the fungal toxin myriocin and is a structural analog of the cellular bioactive sphingolipid sphingosine (Sph). The major source of Sph in cells is via the breakdown of ceramide (Cer), another bioactive sphingolipid and a potent signaling molecule for inflammation and cell death. Sph can be converted back to Cer through a salvage pathway, or can serve as substrate for two kinases, Sphingosine kinase 1 (SPHK1) and SPHK2, to generate another important pleiotropic signaling sphingolipid, sphingosine 1-phosphate (S1P). S1P mediates multiple intracellular functions important for cellular survival, essentially acting in opposition to Cer. S1P also serves as a ligand for a family of five known G-protein coupled receptors, S1PR1–5, which are present on endothelial cells, neuronal cells, and immune cells, and modulate cell migration, cell adhesion, inflammation, and new vessel formation5–14.

Being an analog of Sph, FTY720 is rapidly phosphorylated to FTY720-P by both SPHK1 and SPHK2, at which point the phosphorylated form mimics S1P. This conversion primarily occurs in the liver via SPHK215–19. Genomic analysis reports that expression of SPHK1 is highest among lung and spleen tissue while SPHK2 is preferentially expressed in the heart and liver16,20,21. Although the two enzymes’ conserved domains share 80% homology, they exhibit distinct kinetic differences: SPHK2 is quantitatively 30-fold more efficient at phosphorylating FTY720 compared to SPHK1 due to the drug’s lower Km towards the second isotype15,18,19. Thus, most FTY720 is converted to FTY720-P in the liver by SPHK2.
We have shown previously that systemic dosing of FTY720 before exposure to intense, damaging light provides significant protection to photoreceptor cells from apoptotic cell death. From the kinetics of FTY720-mediated prevention of in vivo photoreceptor cell death in animal models, it appears that the unphosphorylated form of FTY720 provides sufficient protection from apoptotic cascades. FTY720 treatment completely blocked intense light exposure-induced ceramide increases prior to cell death. We found that Cer plays a crucial role in light-induced degeneration of photoreceptor cells and were able to conclude that FTY720 prevents excess Cer formation during light exposure. We have also shown in our in vitro studies that reduction of Cer by overexpression of acid Ceramidase (ASAH1), a lysosomal enzyme which degrades excess Cer, in retinal pigment epithelial (RPE) cells provides significant protection from oxidative stress-induced cell death, further highlighting the role of Cer in retinal degeneration.

Retinal photoreceptor cell death by apoptosis is the hallmark of major retinal degenerative diseases such as retinitis pigmentosa (RP), and is also a major component of diabetic retinopathy (DR) and age-related macular degeneration (AMD). So far, no effective therapies have been developed for this group of diseases. Our findings that FDA-approved FTY720 plays an active, protective role in the prevention of retinal cell death opened the door to many potential avenues for further investigation of the complex pathophysiology of human retinal degenerative diseases and potential therapy development. However, it is important to understand the actual mechanisms of FTY720 in retinal protection, as it can act as a pleiotropic molecule in addition to its known effect of inhibiting de novo Cer synthesis. As a mimic of bioactive S1P, FTY720-P can have a multitude of actions and signaling roles in mammalian systems that may directly or indirectly affect the fate of photoreceptors during light exposure. The current understanding of the mechanisms driving these effects is far from complete and must be further developed. To that end, we designed the present study to test whether it is FTY720 or FTY720-P that is ultimately responsible for previously-observed photoreceptor protection in light-stressed murine models. We converted Sphk2 knockout (KO) mice (which are severely deficient in their ability to phosphorylate FTY720 to FTY720-P) to an albino background (which is vulnerable to light-induced retinal damage) and administered FTY720 intraperitoneally prior to subjecting them to a period of intense light stress designed to model photoreceptor damage. Our experiments provided convincing evidence that FTY720 itself can provide protection from light-induced damage to retinal cells without conversion to FTY720-P.

Results

Generation of albino Sphk2 KO mice. We received Sphk2 KO mice on C57BL/6 background from Dr. Richard L. Proia (NIDDK, Bethesda, MD). As pigmented mice are resistant to light-induced retinal degeneration and unsuitable for our model, we generated an albino Sphk2 KO line by 7-generation backcrossing with Balbc mice. After genotyping, heterozygous females were selected from each generation and backcrossed to a parent Balbc male. Like the parent line, the albino line is also viable and fertile.

Visual characterization of Sphk2 KO mice. We conducted basic visual functional characterization of albino Sphk2 KO and wild-type (WT) mice by measuring retinal function using ERG at 3 and 6 months of age. We also analyzed retinal/eye structure with histology. We did not detect any major changes in scotopic ERG A-wave and B-wave (a measure of rod photoreceptor function), aside from a measurable difference in A-wave at the high-intensity flash (2000 cd.s/m²) between the WT and KO mice at 3 months of age (Fig. 1A,B; p < 0.05, n = 12; t-test). Using photopic ERG measuring cone photoreceptor function, no difference was observed with bright white (2000P), green, and blue light. The KO animals (both 3 and 6 months old) showed higher response at 20 Hz flickers, which measure cone photopigment regeneration (Fig. 1C; p < 0.05, n = 12 (3-Mo), n = 10 (6-Mo); t-test). ERG representative traces at different flash intensities of WT and KO mice at 3 and 6 months indicated similar photoreceptor viability between WT and Sphk2 KO mice, suggesting that knockout of the Sphk2 gene does not cause any apparent defects in photoreceptor performance (Supplementary Fig. S1). Histological analysis did not reveal any distinct differences in retinal structure and organization of various layers between KO and WT mice. As expected from the photoreceptor function study, there was no difference in the thickness of the photoreceptor layer in KO mice at 6 months of age (Fig. 1D; n = 4).

Light damage response of Sphk2 KO mice retina and the effect of FTY720. We further characterized Sphk2 KO mice after stressing their retinas with intense light exposure at 1000 lux for 10 hours at night when the mice are alert and active (6 PM to 4 AM). This exposure caused significant reduction in retinal function for both WT and Sphk2 KO mice and no significant differences in retinal functional damage were found between WT and KO mice (Fig. 2A; p < 0.05, n = 6–12; two-way ANOVA with Bonferroni's correction). However, a slight difference in structural damage was observed in the inferior retina, as shown for the vehicle-treated mice exposed to similar light conditions in Fig. 3B (p < 0.05, n = 6–12; two-way ANOVA with Bonferroni's correction). These data indicate that Sphk2 KO mice are almost equally susceptible to light-damage (LD) compared to WT mice.

We wanted to determine whether FTY720 or FTY720-P plays a major role in preventing retinal light damage. Following previously published protocols, 10 mg/kg FTY720 and vehicle (Veh) were delivered systemically via intraperitoneal (IP) injections to Sphk2 KO and WT mice 30 minutes prior to LD. Both WT and KO mice treated with Veh and exposed to LD (VLD) had significantly reduced A-wave response (Fig. 2A; p < 0.05, n = 6–12; two-way ANOVA with Bonferroni's correction). FTY720 treatment prevented reduction in A-wave response completely in both WT and KO mice (Fig. 2A). We observed no significant changes in A-wave responses at any flash intensity among animals treated with FTY720 prior to LD (FLD) from no-light-damaged (NLD) controls, regardless of Sphk2 KO status (Fig. 2A). Similarly, no difference in B-wave response was observed between Veh-treated KO and WT, or between mice treated with FTY720 and NLD (Fig. 2B), indicating LD significantly reduced retinal function in both Veh-treated WT and KO mice. However, we noted complete protection of retinal function from LD when these mice are treated with FTY720 (Fig. 2B). When we looked at cone function by
Figure 1. Functional and Structural characterization of Sphk2 knockout mouse retinas. (A) Rod photoreceptor function measured by dark-adapted scotopic ERG – A wave amplitudes (µV) at 3 and 6 months of age at increasing flash intensities (0.0004–2000 cd.s/m²) and presented in line graph with mean ± S.D. (B) Scotopic ERG B wave amplitudes (µV) at 3 and 6 months of age at increasing flash intensities (0.0004–2000 cd.s/m²) are presented in line graph with mean ± S.D. (C) Cone photoreceptor function measured by ERG at 3 and 6 months of age and photopic B wave amplitudes (µV) are presented in bar graph with mean ± S.D. (D) Outer Nuclear Layer (ONL) thickness measurements are presented in line graph with mean ± S.D. WT, wild-type; KO, Sphk2 knockout; MO, Month; *p < 0.05; †p < 0.05. *Represents significant difference between WT and KO mice in the 3-month group; †represents significant difference between WT and KO mice in the 6-month group.
In photopic ERG, we observed the same trend - FTY720 treatment prevented the loss of cone function in both KO and WT mice similarly (Supplementary Fig. S2).

In Fig. 2C–H, we show the representative images of the superior-central retina of WT and KO mice from various treatments. This part of the murine retina is known to be the most affected by LD30,31. LD caused prominent damage to the photoreceptor cells, as indicated by the reduction of the photoreceptor layer (retinal outer nuclear layer, ONL) in both WT and KO mice treated with Veh (Fig. 2D,G). However, treatment with FTY720 prevented this damage (Fig. 2E,H). When we quantified the damage by morphometric measurement of the ONL, we found that VLD mice had significantly decreased ONL thickness, higher in the superior than the inferior retina. Mice injected with FTY720 prior to LD showed no significant deviation from NLD mice in ONL thickness, regardless of KO or WT genotype. The inferior ONL of vehicle-treated KO mice showed less light-induced degeneration than WT mice, but fewer differences were seen in the superior ONL (Fig. 3). Averaged measurements of ONL thickness at the superior and inferior central retinas showed that Vehicle-treated WT and KO mice subjected to LD had significant reduction of ONL thickness in both the superior and inferior retina, while NLD mice and mice treated with FTY720 had no significant changes in ONL thickness (Supplemental Fig. S3; p < 0.05; two-way ANOVA with Bonferroni’s correction). In summary, LD caused significant damage of retinal structure and function in both WT and KO mice, which is prevented by FTY720 injections prior to LD.

Sphingolipid profile in Sphk2 KO mouse tissues. We analyzed the plasma, liver and retina from Sphk2 KO and WT littermate mice for the major sphingolipids (ceramide, Cer; hexosyl-ceramide, Hex-Cer; sphingomyelin, SM) and long chain base containing species such as Sphingosine (Sph), dihydro sphingosine (DHSph), sphingosine 1-phosphate (SIP), and dihydro sphingosine 1-phosphate (DHS1P) by mass spectrometry. In plasma, we observed significant increases in C24:1 Cer (p < 0.05, n = 4), and both C16:0 and C22:0 Hex-Cers (p < 0.01, n = 4) in Sphk2 KO mice (Fig. 4A,B). In the liver, we detected very significant increases of C16:0 Cer (p < 0.001, n = 4) and C16:0 Hex-Cer (p < 0.05, n = 4), along with decreases in C24:0 Cer (p < 0.05, n = 4) and C22:0 Hex-Cer (p < 0.01, n = 4) (Supplementary Fig. S4). In retinal tissue, however, we only found a significant increase in C18:0 Cer in Sphk2 KO mice (Supplementary Fig. S5; p < 0.05, n = 4, t-test). Knocking out or blocking SPHK2 is known to increase the levels of SIP in the plasma and blood32,33, which might have affected or shifted the sphingolipid metabolism towards the observed profile in the above tissues. No changes were observed in any

Figure 2. Characterization of Sphk2 knockout mouse retina after Light Induced Retinal Damage. Seven days after light-induced retinal damage (LD), photoreceptor function of WT and Sphk2 KO mice injected with either FTY720 or Vehicle was measured using ERG. (A) Rod photoreceptor function measured by dark-adapted scotopic ERG A wave amplitudes (µV) and presented in line graph representing mean ± S.D. (B) Scotopic ERG B wave amplitudes (µV) at 3 and 6 months of age at increasing flash intensities (0.0004–2000 cd.s/m²) are presented in line graph with mean ± S.D. (C–H) Representative H&E-stained sections of both wild-type and knockout mice retinas were imaged from the superior central retina: (C) wild-type no light damage (NLD); (D) wild-type vehicle-injected and light damage (VLD); (E) wild-type FTY720-treated and light damage (FLD); (F) knockout NLD; (G) knockout VLD; (H) knockout FLD. *p < 0.05 WT-VLD vs. WT-NLD; #p < 0.05 KO-VLD vs. KO-NLD. WT, wild-type; KO, Sphk2 knockout; NLD, No Light Damage; VLD, Vehicle + Light Damage; FLD, FTY720 + Light Damage; RPE, retinal pigmented epithelium; PR-OS, photoreceptor outer segment; PR-IS, photoreceptor inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer.
species of SM (Supplementary Figs S4, S5) and these profiles were not changed after 3 hours of systemic treatment with FTY720 at 10 mg/kg (data not shown).

We further confirmed that knocking out of Sphk2 increases the levels of S1P in the plasma. As shown in Fig. 3A, we detected a >2-fold increase in S1P levels in the plasma of KO mice (p < 0.05, n = 6; two-way ANOVA

**Figure 3.** Outer nuclear layer thickness measurements of Sphk2 knockout and wild-type mice subjected to light damage or no light damage and FTY720 intraperitoneal injection. Vehicle injection, or no injection. ONL thickness was measured along the vertical meridian from the superior to the inferior retina and presented with mean ± S.D. (A) WT and KO mice without light damage (NLD). (B) Veh-treated WT and KO mice with light damage (VLD). (C) FTY720-treated WT and KO mice with light damage (FLD). *p < 0.05 WT-VLD vs. KO-VLD. WT, wild-type; KO, Sphk2 knockout.
with Bonferroni's correction). No changes were found in other long-chain sphingosine base (LCB) containing species (Fig. 5A). We also did not find any significant effect of FTY720 treatment on the other LCB levels in either WT or KO mice (Fig. 5A). In the retina, no difference in the LCBs were found due to deletion of $Sphk2$ or treatment with FTY720 (Fig. 5B). In the liver however, deletion of $Sphk2$ was shown to increase S1P levels as well as Sph levels (Fig. 5C; $p < 0.05$, $n = 6$; two-way ANOVA with Bonferroni's correction). However, when these KO mice were treated with FTY720, they had reduced S1P levels in the liver and significant Sph accumulation (Fig. 5C). Therefore, it appears that deactivation of SPHK2, which is the primary form of sphingosine kinase in the liver, slowed or reduced phosphorylation of Sph, causing an accumulation of Sph (in the order of thousandth, where S1P increase is hundredth pmol, which is further increased by FTY720 treatment as FTY720 competes with Sph as substrate for the SPHK enzymes (Fig. 5C).

**Figure 4.** Sphingolipid Species of $Sphk2$ knockout mice in plasma samples. Plasma samples were collected from WT and $Sphk2$ KO mice and analyzed using LC/MS/MS for relative levels of various chain length variants of the major sphingolipid classes: (A) Ceramide, (B) Hexosyl-Ceramide, and (C) Sphingomyelin. Data presented as mole percent composition of each species (mean ± S.D.). WT, wild-type; KO, $Sphk2$ knockout. *$p < 0.05$; **$p < 0.01$. 
Metabolism and bioavailability of FTY720 in Sphk2 KO retina and other tissues. There is no report on FTY720 bioavailability and metabolism in the retina. In this case, we wanted to investigate the conversion and presence of FTY720-P in the retina during light exposure. We therefore measured the absolute levels (pmol/g tissue) of FTY720 and FTY720-P in liver, plasma, and retinal samples from KO and WT mice at 3 hours.
the majority of FTY720 conversion (Fig. 6; \( p < 0.05 \)). Levels of FTY720-P were significantly decreased in all KO mice tissues, illustrating that SPHK2 is responsible for the majority of FTY720 conversion (Fig. 6; \( p < 0.05 \)). Plasma FTY720-P was decreased but not to the extent of liver and retina in KO mice, suggesting that plasma SPHK1 was activated to compensate SPHK2 deletion and thus increased the S1P levels in the plasma (Fig. 5A) and similarly converts FTY720 to FTY720-P.

In order to understand the extent of conversion of FTY720 to FTY720-P and their relative ratio in different tissues, we determined percent ratios of FTY720 to FTY720-P in liver, plasma, and retinal tissue from WT and KO mice. In WT livers 3 hours post-treatment, the ratio of FTY720 to FTY720-P was 30:70, whereas KO mice injected with FTY720 were found to have almost no FTY720-P in liver samples, indicating that inactivation of Sphk2 almost completely prevented phosphorylation of FTY720 in the liver (Fig. 7A; \( n = 6 \)). The plasma samples of KO mice showed markedly decreased FTY720 conversion, though not as profoundly as in the liver. The ratio of FTY720 to FTY720-P was 23:77 in WT plasma and 58:42 in KO plasma, respectively (Fig. 7B; \( n = 6 \)). As mentioned earlier, this is most likely due to compensatory activity of Sphk1, which is a secretory enzyme and found in high concentration in blood and in erythrocytes\(^{34-37} \). Sphk1 has lower conversion efficiency for FTY720 than SPHK2, but it is possible that the inefficiency was offset by the high levels of FTY720 substrate. WT retinas were found to be less efficient in phosphorylating FTY720 than the liver and plasma, as we detected the ratio of FTY720 to FTY720-P to be 60:40 after 3 hours (Fig. 7C; \( n = 3 \)), whereas it was 30:70 and 23:77 in livers and plasma, respectively. It may be possible that expression/activity of Sphk2 in retinal tissue is lower than in liver and plasma. However, phosphorylation of FTY720 decreased significantly in KO retinas, with a ratio of 96:4 (Fig. 7C; \( n = 3 \)). Our data clearly shows that FTY720-P levels are minimal in Sphk2 KO retina. It also suggests that Sphk1 has minimal influence on the amount of FTY720-P reaching the retina. Thus, FTY720 appears to be the active compound preventing photoreceptor degeneration due to light damage and we rule out the effect of FTY720-P in doing so.

**Discussion**

Sphingolipids are vital in maintaining the viability of neuronal tissue. Through cycles of degradation and re-synthesis of different sphingolipid metabolites, sphingolipids can regulate pathways for proliferation, apoptosis, angiogenesis, and migration, and sphingolipid signaling is potentially involved in a variety of mammalian retinal degenerative diseases\(^{22,23,38} \). Our prior findings have implicated systemic FTY720, a Sph analogue and FDA-approved drug, in protection from light- and disease-mediated retinal degeneration\(^{22} \). These findings underscore the potential for development of novel therapeutics which target sphingolipid signaling and metabolic pathways. However, it is necessary to first develop a detailed understanding of FTY720’s metabolism, pleiotropic biological actions, and the mechanisms by which it or its phosphorylated form prevents retinal degeneration. From our previous studies, we hypothesized that FTY720 that prevents retinal degeneration by inhibiting de novo Cer synthesis\(^ {22,23,38} \). In the present study, we used Sphk2 KO mice to determine if FTY720 requires phosphorylation to FTY720-P prior to assuming its protective role in retinal degeneration.

FTY720 is a sphingosine analog which is phosphorylated in mammals to FTY720-P and functions as an agonist for four of the five S1P receptors (1, 3, 4 and 5)\(^ {39,40} \). FTY720 is also an FDA-approved drug for MS; the phosphorylated form of FTY720 is able to sequester circulating lymphocytes, causing lymphopenia\(^ {39-42} \). Independent actions of FTY720 have recently been demonstrated in many cellular activities\(^ {39} \). For instance, FTY720 inhibits the cannabinoid CB1 receptor\(^ {43} \) and cytosolic phospholipase A2 (cPLA2), and counteracts ceramide 1-phosphate-induced cPLA2 activation\(^ {44} \). FTY720 is also known to inhibit S1P lyase, another important enzyme for cellular sphingolipid metabolism and regulation\(^ {45} \). Many studies have shown that hepatic SphK2 is the primary enzyme which phosphorylates FTY720 to FTY720-P, which is assumed to be the biologically active form of the drug, at least in the context of MS\(^ {15-19} \). We previously acquired compelling evidence that

![Figure 6](https://doi.org/10.1038/s41598-019-44047-z)
lymphopenia is not the cause of FTY720-induced retinal protection from light-induced damage. As a result of light-induced damage, the retinal photoreceptors degenerate and undergo apoptosis, but the apoptotic cascade can be blocked by FTY720. FTY720’s action is complex and poorly-understood in the context of retinal protection: the drug is phosphorylated to FTY720-P, which acts as an S1P mimic, and S1P is active in a wide range of cellular processes including growth, differentiation, motility, calcium mobilization, and other processes which are conducive to cell survival. S1P is also important for the development of the vascular system, the heart, and for immunity. The S1P signaling pathway through S1P receptors can induce activation of the small GTPase Rac, phospholipase C, extracellular signal-regulated kinase, protein kinase Akt, phosphatidylinositol 3-kinase, etc. It is therefore important to understand the extent of FTY720-P’s involvement, if any, in retinal protection from apoptosis.

Figure 7. FTY720 and FTY720-P ratio in various tissues of Sphk2 knockout and wild-type mice. The percentage of FTY720 relative to FTY720-Phosphate was measured by LC/MS/MS in both WT and Sphk2 KO mice tissue (mean ± S.D.): (A) liver, (B) plasma, and (C) retinas. WT, wild-type; KO, Sphk2 knockout; FTY, FTY720; FTY-P, FTY720-Phosphate.
FTY720 is primarily phosphorylated in the liver by SPHK2\(^ {15-19} \). We therefore used Sphk2 KO mice generated by Proia group which are severely deficient in their ability to phosphorylate FTY720\(^ {17} \). This line of Sphk2 KO mice, and two other lines developed independently, have no phenotype due to knocking out the Sphk2 gene\(^ {13,18,20} \). We conducted basic visual functional characterization of these mice and did not find any major differences from their WT littermates until 6 months of age (Fig. 1). We found their vulnerability to light-induced damage to be comparable to WT mice. The KO mice have little resistance to damage as evidenced by structural data, but functional deterioration was similar to WT mice. We also found that both Sphk2 KO mice and littermate WT controls are similarly protected from damaging light by FTY720 treatment (Figs 2, 3).

We also determined the bioavailability and metabolism of FTY720 in the retina, liver, and plasma. In Sphk2 KO mice, 3 hours following FTY720 delivery, almost no FTY720-P was found in liver samples, whereas almost 80% of FTY720 was converted to FTY720-P in WT livers, indicating that inactivation of SPHK2 almost completely prevented hepatic phosphorylation of FTY720 (Figs 6, 7). Plasma levels of both FTY720 and FTY720-P were much lower than in the liver (~20 fold) and showed markedly decreased FTY720 conversion in KO samples, though not as profoundly as in the liver (Figs 5, 7). This is likely due to SPHK1, which is present in the plasma and found in higher concentrations in erythrocytes\(^ {34-37} \). KO retinas had significantly decreased FTY720-P, indicating that the liver is the major source for FTY720-P bound for the retina (Figs 6, 7). The retina has very low expression of both Sphk1 and Sphk2 genes\(^ {48} \) and retinal levels of S1P are 30–40 fold lower than plasma levels (Fig. 5B). From mouse and human tissue distribution studies, SPHK2 is expressed mostly in the brain, kidney, liver, lungs, spleen and blood\(^ {36,20,25} \). Our data suggests that SPHK1 has minimal influence in the retina under the Sphk2 KO background. However, there is a chance that circulating plasma FTY720-P may have influenced retinal levels to a minor extent. The retina has a small amount of vasculature which may allow for transfer of SIP and FTY720-P from the plasma. However, we did not see a change in retinal SIP levels suggesting that this transfer is limited (Fig. 5). We have previously noted changes in retinal SIP levels following light-induced damage\(^ {22} \) and our data suggests that FTY720 has higher bioavailability in the retina than FTY720-P (Figs 6, 7). Furthermore, FTY720-P levels were very low (<5%, Fig. 7) in Sphk2 KO retinas. Our previous studies suggest that FTY720 protection of the retina is dose-dependent\(^ {22} \), so the likelihood of a significant protective effect attributable to the very low levels of FTY720-P present in Sphk2 KO retinas is minimal.

Whole retinas were used for measurements of sphingolipid and FTY720 levels, meaning that these measurements are not fully specific to photoreceptors. However, as a very large majority of the murine retina is composed of photoreceptor cells\(^ {49} \), these measurements should closely reflect actual levels of sphingolipids, FTY720, and FTY720-P specific to the photoreceptor cells. Our data therefore strongly suggests that FTY720, rather than FTY720-P, is active in retinal cell protection. They also suggest a potential direct action of FTY720 in the modulation of sphingolipid (Ceramide) signaling in the retina and protection of retinal cells from apoptotic death.

In conclusion, this is the first retinal characterization of Sphk2 KO mice, which are structurally and functionally similar to WT mice of similar background. As expected, these mice are deficient in FTY720 phosphorylation; however, extreme reduction of FTY720-P did not affect retinal protection associated with systemic FTY720 dosage. This observation supports the hypothesis that FTY720 can protect the mammalian retina from apoptotic cell death without phosphorylation. This study is therefore a step towards identifying novel targets in the sphingolipid metabolic pathways for human retinal degenerative diseases causing photoreceptor cell apoptosis, and a step towards potentially developing treatments utilizing FTY720 or related compounds.

Materials and Methods

Animal care. All procedures were performed according to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and the University of Oklahoma Health Sciences Center (OUHSC) and University of Tennessee Health Science Center (UTHSC) Guidelines for Animals in Research. Wild-type (WT) and Sphk2 global knockout (KO) mice (BALB/c background) were generated from pigmented mice that were received from Dr. Richard L. Proia (NIDDK, Bethesda, MD). The mice were born and raised in the Dean A. McGee Eye Institute vivarium at OUHSC and maintained from birth under dim cyclic light (5–10 lux, 12 hours on/off, 7 a.m. to 7 p.m. CST). All mice were genotyped for the retinal degeneration mutations, rd1 and rd8, to ensure they were not present. All procedures, tissue harvest and the methods of euthanasia for mice were reviewed and approved by the OUHSC and UTHSC Institutional Animal Care and Use Committee. Mice were euthanized by carbon dioxide asphyxiation before harvesting the eye or retinal tissues.

Retinal light damage and FTY720 treatment. Light damage was induced by exposing albino Sphk2 KO mice and their WT littermates to damaging white light at an intensity of 1000 lux for 10 hours at night when the mice are alert and active (6 PM to 4 AM). Following light damage, the mice were returned to their normal room for 7 days. After 7 days, visual function was tested by Electoretinography (ERG). Mice were then euthanized via CO2 asphyxiation and their eyes were then harvested for histological analyses.

To determine the protective role of FTY720, FTY720 (Selleck Chemicals; Houston, TX) was dissolved in a vehicle containing sterile DMSO (100%) (Sigma; St Louis, MO) and saline (0.9%) 1:4 (v/v). Mice were treated with a single dose of FTY720 at 10 mg/kg total body weight by IP injection 0.5 hours prior to the start of LD. The vehicle group received only DMSO and saline (1:4) vehicle. 7 days after light damage, the mice were tested using ERG and their eyes were harvested for histology.

Electroretinography (ERG). Flash ERGs were recorded for both eyes with the Diagnosys Espion E2 ERG system (Diagnosys LLC, Lowell, MA) following previously-published protocols\(^ {22,23,30} \). For the assessment of rod photoreceptor function (scotopic ERG), five strobe flash stimuli were presented at flash intensities of 0.0004, 0.04,
4, 400, and 2000 candela (cd)/s²/m². The amplitude of the A-wave was measured from the pre-stimulus baseline to the A-wave trough. Scotopic B-wave response was measured for secondary neurons. The amplitude of the B-wave was measured from the trough of the A-wave to the peak of the B-wave. For the evaluation of cone photoreceptor function (photopic ERG), a strobe flash stimulus (2000 cd/s²/m²) was presented to dilated, light-adapted (5 minutes at 100 cd/s²/m²) mice at 3 and 6 months of age. Cone functional analysis used various flash intensities and frequencies (Photopic 2000, Green, Blue, 3 Hz, 10 Hz, 20 Hz, 30 Hz), under a steady adapting field of 1.7 log cd/s²/m². The amplitude of the cone B-wave was measured from the trough of the A-wave to the peak of the B-wave. Functional characterization was recorded for WT and Sphk2 KO mice at 3 and 6 months of age and seven days after light-induced retinal damage with or without injections of FTY720 or vehicle.

Histology. After ERG recordings, mice were euthanized by carbon dioxide asphyxiation and one or both mouse eyes were enucleated immediately, marked for orientation, placed in fixative (Prefer; Anatech LTD, Battle Creek, MI), and embedded in paraffin for light microscopy evaluation of retinal structure. Sections of 5 μm were cut along the vertical meridian through the optic nerve and stained with hematoxylin and eosin (H & E). The thickness of the outer nuclear layer (ONL) was measured along the vertical meridian every 0.2 – 0.3 μm of the retinal starting from the optic nerve head (ONH) and moving out to the inferior and superior ora serrata. Measured points were plotted as a spider diagram in GraphPad Prism 7.03. ONL thickness was measured for Sphk2 KO and WT mouse retinas at 6 months and for KO and WT mice with or without FTY720 or vehicle injection seven days after light-induced retinal damage.

Extraction and analysis of sphingolipids and FTY720 and FTY720-P. WT and Sphk2 KO animals were treated with 10 mg/kg of FTY720 by IP injection and tissues such as retina, liver, and plasma were harvested after 3 hours. Plasma was also collected to generate SPL profiles of Cer, HexCer, and SM for WT and Sphk2 KO mice without FTY720 injection. Harvested tissues were snap frozen in liquid nitrogen and used for sphingolipid, FTY720, and FTY720-P analyses. Sphingolipids, FTY720, and FTY720-P were analyzed by LC/MS/MS at the Lipidomic Core Facility at Virginia Commonwealth University. We have previously published the procedures for sphingolipid analysis. FTY720 and FTY720-P were also extracted with sphingolipids and integrated with sphingolipid internal standards. FTY720 and FTY720-P were measured in lipid extracts by LC-ESI-MS/MS with the Sciex 5500 QTRAP. Briefly, FTY720 and FTY720-P were analyzed in the same LC-ESI-MS/MS run as sphingolipid bases and sphingoid base 1-phosphates in the positive ion mode with multiple reaction monitoring transitions of m/z 308.0-255.2 and m/z 388.2-255.2 respectively. FTY720 was shown to extract with a similar efficiency to d17:1 Sph, and FTY720-P was shown to extract similarly to d17:1 S1P. To allow for quantitation, standard curves were generated at 0.5 pmol to 1.0 nmol on column for d17:1 Sph, d17:1 S1P, FTY720, and FTY720-P. Based on the relative ionization efficiencies between these curves, conversion factors were applied to areas for the traditional d17:1 Sph and d17:1 S1P internal standards, thus allowing the quantitation of FTY720 and FTY720-P without addition of further internal standards.

Statistics. All statistics were done using GraphPad Prism version 7.03 for Windows (GraphPad Software, La Jolla, CA). Column data were assessed for normality to determine whether to use two-tailed t-tests or Mann-Whitney two-tailed tests (α = 0.05). Grouped data was evaluated by two-way ANOVA (α = 0.05) followed by Bonferroni’s correction for multiple comparisons. For all the data presented, n represents the number of animals. For ERG and histology, data from both eyes were averaged and mean and S.D. were determined from the number of animals.

Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References
1. Aktas, O., Kury, P., Kieseier, B. & Hartung, H. P. fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 6, 373–382, https://doi.org/10.1038/nrneurol.2010.76 (2010).
2. Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362, 402–415, https://doi.org/10.1056/NEJMoa0907839 (2010).
3. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362, 387–401, https://doi. org/10.1056/NEJMoa0909494 (2010).
4. Massberg, S. & von Andrian, U. H. Fingolimod and sphingosine-1-phosphate–modifiers of lymphocyte migration. N Engl J Med 355, 1088–1091, https://doi.org/10.1056/NEJMmp068159 (2006).
5. Allende, M. L., Dreier, J. L., Mandala, S. & Proia, R. L. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 279, 15396–15401, https://doi.org/10.1074/jbc.M314291200 (2004).
6. Allende, M. L., Yamashita, T. & Proia, R. L. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102, 3665–3667, https://doi.org/10.1182/blood-2003-02-0460 (2003).
7. Cinamon, G. et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 5, 713–720, https://doi.org/10.1038/nai1083 (2004).
8. Hla, T., Lee, M. J., Ancellin, N., Paik, J. H. & Kluk, M. J. Lysophospholipids–receptor revelations. J Biol Chem 279, 29367–29373, https://doi.org/10.1074/jbc.M403937200 (2004).
9. Lee, M. J. et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99, 301–312 (1999).
10. Liu, Y. et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106, 951–961, https://doi.org/10.1172/JCI109065 (2000).
11. Liu, Y. et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Biol Chem 279, 29367–29373, https://doi.org/10.1074/jbc.M403937200 (2004).
12. Nat Immunol 5, 713–720, https://doi.org/10.1038/nai1083 (2004).
13. Cell 99, 301–312 (1999).
14. Liu, Y. et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106, 951–961, https://doi.org/10.1172/JCI109065 (2000).
15. Nat Immunol 5, 713–720, https://doi.org/10.1038/nai1083 (2004).
16. Cell 99, 301–312 (1999).
17. Liu, Y. et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106, 951–961, https://doi.org/10.1172/JCI109065 (2000).
18. Nat Immunol 5, 713–720, https://doi.org/10.1038/nai1083 (2004).
19. Cell 99, 301–312 (1999).
20. Liu, Y. et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106, 951–961, https://doi.org/10.1172/JCI109065 (2000).
Acknowledgements
This work was supported by National Eye Institute grants [EY022071, EY025256, EY021725], and grants from Foundation Fighting Blindness Inc., USA and Research to Prevent Blindness Inc., USA. The Lipidomic services [Virginia Commonwealth University (VCU) Lipidomics/Metabolomics Core] and products in support of the study were generated, in part, by the VCU Massey Cancer Center, with funding from National Institutes of Health Grant [P30 CA016059]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Department of Veterans Affairs, or the U.S. government.

Author Contributions
H. Qi, J. Cole, K. Mondal, S. Khanam, S. Dutta, M. Stiles, J. Allegood did experiment and analyzed data; R. Proia, provided materials; R. Grambergs, J. Gillenwater, J. Cole and N. Mandal wrote the paper; N. Mandal designed the experiments, arranged materials and reagents, and arranged IACUC approvals necessary to perform and record data.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-44047-z.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019